Miconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Using txgnn-pipeline to confirm context, then generating the evaluation report per the v5 prompt instructions.
Miconazole: From Fungal Infections to Acne
One-Sentence Summary
Miconazole is a classic imidazole-class antifungal, widely used to treat cutaneous and mucosal fungal infections. The TxGNN model predicts it may be effective for acne (disease), with 1 clinical trial (currently suspended) and 4 publications supporting this direction — including direct in vitro evidence of antibacterial activity against Cutibacterium acnes.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fungal infections (cutaneous / mucosal) |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L3 |
| Philippines Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on established pharmacology, Miconazole is an imidazole-class antifungal that inhibits CYP51 (lanosterol 14α-demethylase), blocking ergosterol biosynthesis in fungal cell membranes. Importantly, this antibacterial spectrum extends beyond fungi to certain gram-positive bacteria — including Cutibacterium acnes (formerly Propionibacterium acnes), the primary bacterial driver of acne vulgaris.
Three mechanistic pathways support this repurposing hypothesis: ① Direct antibacterial activity — in vitro data (PMID 20045949) confirm that azole antifungals, including imidazoles such as miconazole, exhibit measurable inhibitory activity against C. acnes at clinically relevant MIC values. ② Malassezia folliculitis overlap — this condition is frequently misdiagnosed as acne vulgaris, and miconazole is already a standard treatment; this creates a clinically meaningful indirect bridge to the acne indication. ③ Secondary anti-inflammatory effect — imidazole-class agents may suppress prostaglandin synthesis, potentially attenuating the inflammatory papules characteristic of acne.
The overall mechanistic linkage is rated Grade B: biologically plausible with direct in vitro evidence, but high-quality clinical confirmation is still lacking. The TxGNN prediction score of 99.54% reflects strong graph-level signal, though clinical translation requires further validation.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01244256 | Phase 2/3 | Suspended | 80 | Evaluated a combination cream (beclomethasone 0.025% + gentamicin 0.1% + antifungal component) for contaminated dermatosis with bilateral symmetrical lesions. Trial was suspended before completion; no efficacy conclusions can be drawn, and the multi-component design prevents isolation of miconazole’s individual contribution. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18627330 | 2008 | Review | Expert Opinion on Pharmacotherapy | Reviews miconazole nitrate’s multifaceted effects on skin disorders beyond classical antifungal use, highlighting novel therapeutic directions for the imidazole class |
| 15536660 | 2004 | Clinical Assessment (Split-face) | Skin Research and Technology | Split-face clinical assessment of catamenial acne in young women; evaluates a miconazole-containing regimen in the context of cyclically recurrent inflammatory skin changes |
| 8593718 | 1995 | Observational / Case Series | Clinical and Experimental Dermatology | 62 patients with Pityrosporum (Malassezia) folliculitis, frequently misdiagnosed as acne vulgaris; supports the diagnostic overlap rationale and miconazole’s established efficacy in this condition |
| 20045949 | 2010 | In vitro Study | Biological & Pharmaceutical Bulletin | Determines in vitro activities of azole antifungals against Propionibacterium acnes from acne vulgaris patients; provides the most direct mechanistic link, showing clinically relevant anti-C. acnes MIC values for the imidazole class |
Philippines Market Information
Miconazole currently has no registered products in the Philippines. There are no FDA Philippines authorization numbers on record, and the drug is classified as not marketed. Any clinical use in the Philippines would require a new drug registration submission before commercial adoption.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The sole registered clinical trial (NCT01244256) was suspended before completion and used a multi-component formulation that cannot isolate miconazole’s individual contribution; available literature consists of one review, one small split-face clinical assessment, one observational case series, and one in vitro study — an evidence base insufficient for a repurposing adoption decision, particularly given zero Philippines market registrations and missing safety data.
To proceed, the following is needed:
- A dedicated randomized controlled trial evaluating topical miconazole monotherapy in confirmed acne vulgaris
- Retrieval of MOA data from DrugBank (DG002) to formally document the mechanistic rationale
- Philippines FDA package insert review to characterize key warnings and contraindications (DG001)
- Philippines FDA registration pathway assessment — a new drug application or bridging strategy will be required prior to any commercialization
- Dose-response and formulation characterization for the acne indication (optimal topical concentration, vehicle, and treatment duration)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.